Evolus, Inc. (EOLS)
Stock Price:
$5.48 USD
0.08 (1.48%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
184.83M |
| Revenue (ttm) |
45.42M |
| Net Income (ttm) |
-98.79M |
| Shares Out |
33.73M |
| EPS (ttm) |
-3.31 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 2, 2020 |
| Last Price |
$5.48 |
| Previous Close |
$5.40 |
| Change ($) |
0.08 |
| Change (%) |
1.48% |
| Day's Open |
5.50 |
| Day's Range |
5.26 - 5.62 |
| Day's Volume |
298,137 |
| 52-Week Range |
3.12 - 20.27 |
More Stats
| Market Cap |
184.83M |
| Enterprise Value |
182.16M |
| Earnings Date (est) |
Jul 30, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
33.73M |
| Float |
19.30M |
| EPS (basic) |
-3.37 |
| EPS (diluted) |
-3.31 |
| FCF / Share |
-3.18 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
5.00M |
| Short Ratio |
3.12 |
| Short % of Float |
22.12% |
| Beta |
3.14 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
4.07 |
| PB Ratio |
2.88 |
| Revenue |
45.42M |
| Operating Income |
-91.07M |
| Net Income |
-98.79M |
| Free Cash Flow |
-107.37M |
| Net Cash |
2.67M |
| Net Cash / Share |
0.08 |
| Gross Margin |
59.25% |
| Operating Margin |
-200.51% |
| Profit Margin |
-217.50% |
| FCF Margin |
-236.40% |
| ROA |
-29.22% |
| ROE |
-143.22% |
| ROIC |
-60.30% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (8)
| Buy |
6 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
1 |
Price Target
$14.75*
(169.16% upside)
Low
4.00
Current: 5.48
High
35.00
Target: 14.75
*Average 12-month price target from 8 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | 34.93 | - | - | - | - |
| Gross Profit | 26.91 | - | - | - | - |
| Operating Income | -98.95 | -46.14 | -11.73 | -19.97 | -30.98 |
| Net Income | -90.03 | -46.87 | -4.48 | -20.07 | -31.11 |
| Shares Outstanding | 28.24 | 24.40 | 16.53 | 16.53 | 16.53 |
| Earnings Per Share | -3.19 | -1.92 | -0.27 | -1.21 | -1.88 |
| Operating Cash Flow | -93.38 | -25.67 | -13.22 | -13.27 | -36.38 |
| Capital Expenditures | -4.57 | -0.01 | - | - | - |
| Free Cash Flow | -97.95 | -25.68 | -13.22 | -13.27 | -36.38 |
| Cash & Equivalents | 130 | 93.16 | 0.00 | 0.19 | 4.00 |
| Total Debt | 96.55 | 16.90 | 211 | 59.76 | 46.17 |
| Net Cash / Debt | 33.26 | 76.26 | -211 | -59.57 | -42.17 |
| Assets | 240 | 172 | 152 | 77.50 | 81.30 |
| Liabilities | 161 | 87.46 | 228 | 84.60 | 69.30 |
| Book Value | 79.46 | 84.38 | -75.54 | -7.11 | 12.00 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Evolus, Inc. |
| Country |
United States |
| Employees |
220 |
| CEO |
David Moatazedi |
Stock Information
| Ticker Symbol |
EOLS |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Drug Manufacturers—Specialty & Generic |
| Unique Identifier |
NASDAQ: EOLS |
| IPO Date |
February 8, 2018 |
Description
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California.